Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2026-01-02 @ 1:12 AM
Study NCT ID:
NCT04055493
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-26
First Post:
2019-07-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
Sponsor:
West German Study Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-07-02
Start Date Type:
ACTUAL
Primary Completion Date:
2027-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-07-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-07-22
First Submit QC Date:
None
Study First Post Date:
2019-08-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-25
Last Update Post Date:
2025-08-26
Last Update Post Date Type:
ESTIMATED